Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Amarin Yönetim

Yönetim kriter kontrolleri 1/4

Amarin's CEO'su Aaron Berg, Jun2024 tarihinde atandı, in görev süresi bir yıldan az. in toplam yıllık tazminatı $ 2.45M olup, şirket hissesi ve opsiyonları dahil olmak üzere 25.4% maaş ve 74.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.2% ine doğrudan sahiptir ve bu hisseler € 456.11K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.4 yıl ve 1.7 yıldır.

Anahtar bilgiler

Aaron Berg

İcra Kurulu Başkanı

US$2.4m

Toplam tazminat

CEO maaş yüzdesi	25.4%
CEO görev süresi	less than a year
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	2.4yrs
Yönetim Kurulu ortalama görev süresi	1.7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Aaron Berg'un ücretlendirmesi Amarin'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$34m
Mar 31 2024	n/a	n/a	-US$53m
Dec 31 2023	US$2m	US$622k	-US$59m
Sep 30 2023	n/a	n/a	-US$52m
Jun 30 2023	n/a	n/a	-US$38m
Mar 31 2023	n/a	n/a	-US$91m
Dec 31 2022	US$2m	US$567k	-US$106m
Sep 30 2022	n/a	n/a	-US$92m
Jun 30 2022	n/a	n/a	-US$100m
Mar 31 2022	n/a	n/a	-US$22m
Dec 31 2021	US$3m	US$505k	US$8m
Sep 30 2021	n/a	n/a	-US$2m
Jun 30 2021	n/a	n/a	US$4m
Mar 31 2021	n/a	n/a	US$927k
Dec 31 2020	US$4m	US$458k	-US$18m
Sep 30 2020	n/a	n/a	-US$16m
Jun 30 2020	n/a	n/a	-US$13m
Mar 31 2020	n/a	n/a	-US$19m
Dec 31 2019	US$3m	US$438k	-US$23m

Tazminat ve Piyasa: Aaron 'nin toplam tazminatı ($USD 2.45M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 811.38K ).

Tazminat ve Kazançlar: Aaron şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Aaron Berg (61 yo)

less than a year

Görev süresi

US$2,448,149

Tazminat

Mr. Aaron D. Berg is President & CEO at Amarin Corporation plc since June 2024 and serves as its Director. He had been Executive VP & President of U.S. at Amarin Corporation plc until June 2024 and served...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Aaron Berg	CEO, President & Director	less than a year	US$2.45m	0.20% € 430.0k
Thomas Reilly	Executive VP	2.3yrs	US$2.20m	0.023% € 50.4k
Steven Ketchum	Executive VP	8.8yrs	US$2.35m	0.16% € 358.2k
Jonathan Provoost	Executive VP	less than a year	US$659.26k	Veri yok
Jordan Zwick	Senior VP of Corporate Business Development & Investor Relations	2.4yrs	Veri yok	Veri yok
Laurent Abuaf	President of Europe & Senior VP	no data	Veri yok	Veri yok
Nabil Abadir	Chief Medical Officer of Global Medical Affairs	2.5yrs	Veri yok	Veri yok
David Keenan	Executive VP of Technical Operations & President of Europe	2.4yrs	Veri yok	Veri yok

2.4yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: EH3A 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Aaron Berg	CEO, President & Director	no data	US$2.45m	0.20% € 430.0k
John Climax	Chairman of Scientific Advisory Board	18.4yrs	US$39.00k	Veri yok
Jan Wallace	Member of Scientific Advisory Board	18.4yrs	Veri yok	Veri yok
Mark Pierce	Member of the Scientific Advisory Board	18.4yrs	Veri yok	Veri yok
Reid Patterson	Member of the Scientific Advisory Board	18.4yrs	Veri yok	Veri yok
Louis Sterling	Independent Non-Executive Director	1.7yrs	US$629.35k	0.016% € 35.1k
Odysseas Kostas	Independent Non-Executive Chairperson of the Board	1.7yrs	US$650.41k	0% € 0
Diane Sullivan	Independent Non-Executive Director	1.7yrs	US$630.83k	0% € 0
Keith Horn	Independent Non-Executive Director	1.7yrs	US$632.09k	0% € 0
Mark DiPaolo	Independent Non-Executive Director	1.7yrs	US$621.00k	0% € 0
Patrice Bonfiglio	Independent Non-Executive Director	1.7yrs	US$626.87k	0% € 0
Paul Cohen	Independent Non-Executive Director	1.7yrs	US$622.06k	0% € 0

1.7yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: EH3A 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.7 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Amarin Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Amarin Corporation plc Announces Executive Changes

CEO & President recently bought €94k worth of stock

Amarin Corporation plc Announces Executive Changes

Amarin Corporation plc, Annual General Meeting, Apr 18, 2024

Amarin Corporation plc Appoints Jonathan Provoost as New Executive Vice President, Chief Legal & Compliance Officer, Effective November 15, 2023

President recently bought €286k worth of stock

Recent updates

Amarin Corporation plc Announces Executive Changes

Amarin Corporation plc to Report Q3, 2024 Results on Oct 30, 2024

Now 22% overvalued

Now 22% overvalued

New major risk - Revenue and earnings growth

Now 16% overvalued

CEO & President recently bought €94k worth of stock

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: EPS: US$0.004 (vs US$0.043 loss in 2Q 2023)

Amarin Receives National Reimbursement for Vazkepa® (Icosapent Ethyl) in Portugal

Amarin Corporation plc to Report Q2, 2024 Results on Jul 31, 2024

Amarin Corporation plc Announces Executive Changes

Amarin Corporation Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement of its ADSs Pursuant to Nasdaq Listing Rule 5450(a)(1)

Amarin Corporation plc Receives National Reimbursement for Vazkepa (Icosapent Ethyl) in Greece by Greek Ministry of Health

New minor risk - Profitability

New minor risk - Shareholder dilution

Amarin Corporation plc (NasdaqGM:AMRN) announces an Equity Buyback for $50 million worth of its shares.

Amarin Corporation plc (NasdaqGM:AMRN) announces an Equity Buyback for $50 million worth of its shares.

Amarin Corporation plc to Report Q1, 2024 Results on May 01, 2024

Amarin Corporation plc Announces New Reduce-It® Analyses Show Vascepa®/Vazkepa® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Amarin Corporation plc, Annual General Meeting, Apr 18, 2024

Full year 2023 earnings released: US$0.14 loss per share (vs US$0.26 loss in FY 2022)

Amarin Corporation plc to Report Q4, 2023 Results on Feb 29, 2024

Amarin Regains Compliance with Nasdaq Listing Rule

Amarin Corporation plc Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Now 21% undervalued after recent price drop

Amarin Corporation Receives Non-Compliance Notice from Nasdaq

Amarin Corporation Receives Non-Compliance Notice from Nasdaq

Third quarter 2023 earnings released: US$0.047 loss per share (vs US$0.013 loss in 3Q 2022)

Amarin Corporation plc Appoints Jonathan Provoost as New Executive Vice President, Chief Legal & Compliance Officer, Effective November 15, 2023

Amarin Corporation plc to Report Q3, 2023 Results on Nov 01, 2023

President recently bought €286k worth of stock

Second quarter 2023 earnings released: US$0.043 loss per share (vs US$0.18 loss in 2Q 2022)

Amarin Corporation plc to Report Q2, 2023 Results on Aug 02, 2023

Amarin Corporation plc, Annual General Meeting, Jul 21, 2023

Amarin Corporation plc, Annual General Meeting, Jun 21, 2023

Amarin Corporation plc Highlights New Data Providing Potential Mechanistic Insight into Vascepa(R)/Vazkepa(R) (Icosapent Ethyl)

First quarter 2023 earnings released: US$0.041 loss per share (vs US$0.079 loss in 1Q 2022)

Full year 2022 earnings released: US$0.26 loss per share (vs US$0.02 profit in FY 2021)

Sarissa Capital Releases Investor Presentation to Shareholders of Amarin Corporation

Sarissa Capital Management Issues a Statement Regarding Amarin Corporation

Sarissa Capital Management Issues a Statement Regarding Amarin Corporation

Sarissa Capital Discloses its Views on Amarin Corporation

Sarissa Capital Warns of Amarin’s Expensive Attempts to Switch Votes by Inundating Shareholders with White Proxy Cards

Sarissa Capital Issues a Press Release to Shareholders of Amarin Corporation

Sarissa Capital Issues a Letter to Shareholders of Amarin Corporation

Sarissa Capital Issues a Social Media Post by Alexander J. Denner Relating to Amarin Corporation

Sarissa Capital Issues a presentation to Shareholders of Amarin Corporation

Sarissa Capital Issues an Investor Presentation to Shareholders of Amarin Corporation

Amarin Corporation plc, Annual General Meeting, Feb 28, 2023

Amarin Corporation Provides Information to Shareholders

Amarin Corporation plc Announces VAZKEPA (Icosapent Ethyl) Approved By Medsafe In New Zealand

Sarissa Capital Calls Out Amarin’s Sham Board Refreshment

Sarissa Capital Sends a Requisition Notice to Amarin Corporation

Sarissa Capital Sends a Requisition Notice to Amarin Corporation

Amarin Corporation plc Provides Revenue Guidance for the the Fourth Quarter and Full Year 2022

High number of new directors

Amarin Corporation plc Announces Board Changes

Amarin Corporation plc Enters into Settlement Agreement with Health Net, LLC

Amarin Corporation plc's Vazkepa (Icosapent Ethyl) Receives Regulatory Approval in Switzerland

Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia

Amarin Appoints Adam Berger and Geraldine Murphy to Board of Directors

Amarin Corporation plc Announces New Reduce-It(R) Data Show Vascepa(R)/Vazkepa(R) (Icosapent Ethyl) Reduced Stemi as Well as Other Mi Subtypes

Amarin Corporation plc Announces New Research on the Effects of VASCEPA®/VAZKEPA at the European Society of Cardiology Congress

Amarin Corporation plc Suspends Revenue Guidance for the Year 2022

Amarin Corporation plc to Report Q2, 2022 Results on Aug 03, 2022

Sarissa Capital Management LP Provides Information to Shareholders of Amarin Corporation plc

Amarin Corporation plc Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction

Amarin Corporation plc Announces Executive Changes